Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.

Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M, Verneris M, Wagner J, Dusenbery K, Aurora M, Bachanova V, Brunstein C, Burns L, Cooley S, Kaufman D, Majhail NS, McClune B, McGlave P, Miller J, Oran B, Slungaard A, Vercellotti G, Weisdorf DJ.

Biol Blood Marrow Transplant. 2011 Jul;17(7):1025-32. doi: 10.1016/j.bbmt.2010.10.030. Epub 2010 Nov 1.

2.

Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.

Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT.

Leukemia. 2003 May;17(5):841-8. Review.

PMID:
12750695
4.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
5.

Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia.

Blaise D, Vey N, Faucher C, Mohty M.

Haematologica. 2007 Apr;92(4):533-41. Review.

6.

Allogeneic stem cell transplantation in follicular lymphoma.

Khouri IF.

Best Pract Res Clin Haematol. 2011 Jun;24(2):271-7. doi: 10.1016/j.beha.2011.03.008. Epub 2011 May 5. Review.

7.

Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia.

Gribben JG, Hosing C, Maloney DG.

Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S63-70. doi: 10.1016/j.bbmt.2010.10.011. Review.

8.

Hematopoietic stem cell transplantation for MDS.

Bartenstein M, Deeg HJ.

Hematol Oncol Clin North Am. 2010 Apr;24(2):407-22. doi: 10.1016/j.hoc.2010.02.003. Review.

9.

Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.

Capria S, Barberi W, Perrone S, Ferretti A, Salaroli A, Annechini G, D'Elia GM, FoĆ  R, Pulsoni A.

Expert Rev Hematol. 2016 Oct;9(10):951-64. doi: 10.1080/17474086.2016.1226128. Epub 2016 Aug 31. Review.

PMID:
27539362
10.

A Review of Hematopoietic Cell Transplantation in Australia and New Zealand, 2005 to 2013.

Nivison-Smith I, Bardy P, Dodds AJ, Ma DD, Aarons D, Tran S, Wilcox L, Szer J.

Biol Blood Marrow Transplant. 2016 Feb;22(2):284-91. doi: 10.1016/j.bbmt.2015.09.009. Epub 2015 Sep 16. Review.

11.

[Non-myeloablative therapy and allogeneic hematopoietic stem cell transplantation in hematologic malignancies].

Hansz J.

Pol Arch Med Wewn. 2001;105 Suppl:173-5. Review. Polish. No abstract available.

PMID:
12412244
12.

Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.

van Besien K.

Curr Opin Oncol. 2011 Nov;23(6):681-91. doi: 10.1097/CCO.0b013e32834bb88e. Review.

13.

Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction.

Strober S, Spitzer TR, Lowsky R, Sykes M.

Semin Immunol. 2011 Aug;23(4):273-81. doi: 10.1016/j.smim.2011.05.001. Epub 2011 Jun 25. Review.

14.

Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemia.

Goyal G, Gundabolu K, Vallabhajosyula S, Silberstein PT, Bhatt VR.

Ther Adv Hematol. 2016 Jun;7(3):131-41. doi: 10.1177/2040620716643493. Epub 2016 Apr 22. Review.

15.

Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens.

Saber W, Horowitz MM.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):478-484. Review.

PMID:
27913519
16.

Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.

Salit RB, Deeg HJ.

Hematol Oncol Clin North Am. 2014 Dec;28(6):1023-35. doi: 10.1016/j.hoc.2014.08.003. Epub 2014 Oct 3. Review.

17.

Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors.

Savarese DM, Hsieh C, Stewart FM.

J Clin Oncol. 1997 Aug;15(8):2981-95. Review.

PMID:
9256143
18.

Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.

Cheson BD, Brugger W, Damaj G, Dreyling M, Kahl B, Kimby E, Ogura M, Weidmann E, Wendtner CM, Zinzani PL.

Leuk Lymphoma. 2016;57(4):766-82. doi: 10.3109/10428194.2015.1099647. Epub 2015 Nov 23. Review.

19.

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.

Fenske TS, Hamadani M, Cohen JB, Costa LJ, Kahl BS, Evens AM, Hamlin PA, Lazarus HM, Petersdorf E, Bredeson C.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1543-51. doi: 10.1016/j.bbmt.2016.04.019. Epub 2016 Apr 27. Review.

20.

Hematopoietic Cell Transplantation for Older Patients with MDS.

Shadman M, Deeg HJ.

Mediterr J Hematol Infect Dis. 2014 Sep 1;6(1):e2014056. doi: 10.4084/MJHID.2014.056. eCollection 2014. Review.

Supplemental Content

Support Center